THERACAT is a Marie Skłodowska-Curie European Training Network (MSCA-ITN-ETN) coordinated by IBEC, aiming to train a new generation of researchers on the innovative topic of bio-orthogonal catalysis for cancer therapy.
THERACAT is focused on the development of catalysis-based approaches towards the cure of cancer. In this strategy nano- and micro-particles bearing a catalytic unit are delivered to the tumour site and subsequently non-active prodrugs are administered to the patient. The prodrugs are non-toxic and therefore generate limited side effects. Only at the tumour site the catalytic particles convert the prodrugs into active anticancer compounds that generate a local and strong effect, as single catalytic species can uncage a large number of drugs. This approach presents several advantages on the classical drug delivery paradigm including limited side effects and prolonged efficacy.
You can find the program and the registration form at the following website:
The titles of the presentations will be updated next week and the link to attend remotely to the conference will be sent by e-mail.